Tokyo, Sept 29, 2009 (JCN Newswire) - Eisai Co., Ltd. and the Drugs for Neglected Diseases initiative (DNDi), a non-profit independent foundation, announced today that they have signed a collaboration and license agreement for the clinical development of a promising new drug for the treatment of Chagas disease, a fatal infectious disease that threatens 100 million people in Latin America and the Caribbean.
